ReviewClinical journal of gastroenterology2018
The evidence for fungus in Crohn's disease pathogenesis.
Review in Clinical journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- The transcriptome of dendritic cells redraws the boundaries between pathogenicity and commensalism in yeast.Microbial cell (Graz, Austria) · 2026Article
- Role ofWorld journal of gastroenterology · 2024Review
- Glucocorticoid-Induced Leucine Zipper Protein and Yeast-Extracted Compound Alleviate Colitis and Reduce Fungal Dysbiosis.Biomolecules · 2024Article
- The Role of Host Genetics and Intestinal Microbiota and Metabolome as a New Insight into IBD Pathogenesis.International journal of molecular sciences · 2024Review
- Fungal Microbiota Composition in Inflammatory Bowel Disease Patients: Characterization in Different Phenotypes and Correlation With Clinical Activity and Disease Course.Inflammatory bowel diseases · 2024Article
- Impact of cooperative or competitive dynamics between the yeastFrontiers in immunology · 2024Review
- Fecal Fungal Microbiota (Mycobiome) Study as a Potential Tool for Precision Medicine in Inflammatory Bowel Disease.Gut and liver · 2023Review
- Individuals with Inflammatory Bowel Disease Have an Altered Gut Microbiome Composition of Fungi and Protozoa.Microorganisms · 2022Article
- The Neglected Gut Microbiome: Fungi, Protozoa, and Bacteriophages in Inflammatory Bowel Disease.Inflammatory bowel diseases · 2022Review
- The Gut-Brain Axis in Inflammatory Bowel Disease-Current and Future Perspectives.International journal of molecular sciences · 2021Review
- LncRNA LUCAT1 as a Plasma Biomarker for Assessing Disease Activity in Adult Patients with Crohn's Disease.Gastroenterology research and practice · 2021Article
- The role of gastrointestinal pathogens in inflammatory bowel disease: a systematic review.Therapeutic advances in gastroenterology · 2021Review
- Comparative immunophenotyping ofJournal of translational autoimmunity · 2020Article
- Innate Lymphoid Cells in Crohn's Disease.Frontiers in immunology · 2020Review
- Microscopic features of small bowel mucosa of patients with Crohn's disease.BMC gastroenterology · 2019Article
- Gastrointestinal microbiota alteration induced by Mucor circinelloides in a murine model.Journal of microbiology (Seoul, Korea) · 2019Article
- Circular RNA expression profile in peripheral blood mononuclear cells from Crohn disease patients.Medicine · 2019Article
- The Impact of DNA Extraction Methods on Stool Bacterial and Fungal Microbiota Community Recovery.Frontiers in microbiology · 2019Article
- Bacterial but Not Fungal Gut Microbiota Alterations Are Associated With Common Variable Immunodeficiency (CVID) Phenotype.Frontiers in immunology · 2019Article
- The intestinal microbiota in the pathogenesis of inflammatory bowel diseases: new insights into complex disease.Clinical science (London, England : 1979) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Current evidence suggests the etiology of inflammatory bowel diseases (IBD) involves the confluence of host genetic, environmental, and microbial factors that lead to chronic, and often refractory, disease in susceptible individuals. The involvement of microbial triggers in IBD, including Crohn's disease (CD), is increasingly evident with supporting data provided with advancements in metagenomic sequencing that have identified perturbations in microbial structure and function-broadly termed dysbiosis-in CD patients compared with healthy subjects. This concept is supported by the finding germ-free animals with CD genetic susceptibility fail to develop disease; demonstrating microorganisms are necessary but not sufficient for CD. The vast majority of CD microbiome research has focused on the complex bacterial communities and microbiome dysbiosis in the gut with 16S metagenomic sequencing. However, emerging data capturing eukaryotes suggest fungal opportunistic pathogens are also associated with IBD pathogenesis and chronicity. This hypothesis is further supported by historical observations that CD patient populations display elevated antibodies against fungal targets, even evident before disease diagnosis. This review discusses the current findings in the field, followed by historical and metagenomic evidence for fungal pathogens in the development and recurrence of CD in adult and pediatric populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.